Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports

Novartis paused eight clinical trials in late August after three patients died following treatment with an experimental therapy targeting autoimmune and neurological disorders. The pause, reported by the WSJ, raises near-term safety/regulatory risk for the program and could weigh on sentiment around the drug’s development path.